11Boron delivery agents for boron proton-capture enhanced proton therapy

K. Hideghéty, Szilvia Brunner, Andrew Cheesman, Emilia Rita Szabó, Róbert Polanek, Daniele Margarone, Tünde Tőkés, K. Mogyorósi

Research output: Contribution to journalReview article

Abstract

The aim of this review was to define appropriate 11B delivery agents for boron proton-capture enhanced proton therapy (BPCEPT) taking into account the accumulated knowledge on boron compounds used for boron neutron capture therapy (BNCT). BPCEPT is a promising treatment approach which uses a high linear energy transfer (LET) dose component in conjunction with conventional proton therapy to increase the relative biological effectiveness of highly-selective charged particle therapy. Boron proton fusion reactions occur with highest cross section at certain proton energy level and thus can be tailored to the target volume with careful treatment planning that defines the 675 MeV proton distribution with high accuracy. Appropriate 11B compounds are required in order to achieve relevant high LET dose contribution from the boron proton-capture reaction. Previous scientific results and experiences with BNCT provide background knowledge and information regarding the optimization of boronated compound development, their characterization, measurement and imaging. However, there are substantial differences between BNCT and BPCEPT, which in turn places special unique chemical, physical and biological demands on 11B-carrier compounds for BPCEPT. In this review, we evaluate well-known and recently developed boron compounds for BPCEPT.

Original languageEnglish
Pages (from-to)2265-2276
Number of pages12
JournalAnticancer research
Volume39
Issue number5
DOIs
Publication statusPublished - May 1 2019

Fingerprint

Proton Therapy
Boron
Protons
Boron Compounds
Boron Neutron Capture Therapy
Linear Energy Transfer
Relative Biological Effectiveness
Therapeutics

Keywords

  • BNCT
  • Boron delivery agents
  • Boron-neutron capture therapy
  • Boron-proton capture enhanced proton therapy BPCEPT
  • Review

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

11Boron delivery agents for boron proton-capture enhanced proton therapy. / Hideghéty, K.; Brunner, Szilvia; Cheesman, Andrew; Szabó, Emilia Rita; Polanek, Róbert; Margarone, Daniele; Tőkés, Tünde; Mogyorósi, K.

In: Anticancer research, Vol. 39, No. 5, 01.05.2019, p. 2265-2276.

Research output: Contribution to journalReview article

Hideghéty, K, Brunner, S, Cheesman, A, Szabó, ER, Polanek, R, Margarone, D, Tőkés, T & Mogyorósi, K 2019, '11Boron delivery agents for boron proton-capture enhanced proton therapy', Anticancer research, vol. 39, no. 5, pp. 2265-2276. https://doi.org/10.21873/anticanres.13343
Hideghéty K, Brunner S, Cheesman A, Szabó ER, Polanek R, Margarone D et al. 11Boron delivery agents for boron proton-capture enhanced proton therapy. Anticancer research. 2019 May 1;39(5):2265-2276. https://doi.org/10.21873/anticanres.13343
Hideghéty, K. ; Brunner, Szilvia ; Cheesman, Andrew ; Szabó, Emilia Rita ; Polanek, Róbert ; Margarone, Daniele ; Tőkés, Tünde ; Mogyorósi, K. / 11Boron delivery agents for boron proton-capture enhanced proton therapy. In: Anticancer research. 2019 ; Vol. 39, No. 5. pp. 2265-2276.
@article{3b30e9c52c75484ba7378ce2130409c0,
title = "11Boron delivery agents for boron proton-capture enhanced proton therapy",
abstract = "The aim of this review was to define appropriate 11B delivery agents for boron proton-capture enhanced proton therapy (BPCEPT) taking into account the accumulated knowledge on boron compounds used for boron neutron capture therapy (BNCT). BPCEPT is a promising treatment approach which uses a high linear energy transfer (LET) dose component in conjunction with conventional proton therapy to increase the relative biological effectiveness of highly-selective charged particle therapy. Boron proton fusion reactions occur with highest cross section at certain proton energy level and thus can be tailored to the target volume with careful treatment planning that defines the 675 MeV proton distribution with high accuracy. Appropriate 11B compounds are required in order to achieve relevant high LET dose contribution from the boron proton-capture reaction. Previous scientific results and experiences with BNCT provide background knowledge and information regarding the optimization of boronated compound development, their characterization, measurement and imaging. However, there are substantial differences between BNCT and BPCEPT, which in turn places special unique chemical, physical and biological demands on 11B-carrier compounds for BPCEPT. In this review, we evaluate well-known and recently developed boron compounds for BPCEPT.",
keywords = "BNCT, Boron delivery agents, Boron-neutron capture therapy, Boron-proton capture enhanced proton therapy BPCEPT, Review",
author = "K. Hidegh{\'e}ty and Szilvia Brunner and Andrew Cheesman and Szab{\'o}, {Emilia Rita} and R{\'o}bert Polanek and Daniele Margarone and T{\"u}nde Tők{\'e}s and K. Mogyor{\'o}si",
year = "2019",
month = "5",
day = "1",
doi = "10.21873/anticanres.13343",
language = "English",
volume = "39",
pages = "2265--2276",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5",

}

TY - JOUR

T1 - 11Boron delivery agents for boron proton-capture enhanced proton therapy

AU - Hideghéty, K.

AU - Brunner, Szilvia

AU - Cheesman, Andrew

AU - Szabó, Emilia Rita

AU - Polanek, Róbert

AU - Margarone, Daniele

AU - Tőkés, Tünde

AU - Mogyorósi, K.

PY - 2019/5/1

Y1 - 2019/5/1

N2 - The aim of this review was to define appropriate 11B delivery agents for boron proton-capture enhanced proton therapy (BPCEPT) taking into account the accumulated knowledge on boron compounds used for boron neutron capture therapy (BNCT). BPCEPT is a promising treatment approach which uses a high linear energy transfer (LET) dose component in conjunction with conventional proton therapy to increase the relative biological effectiveness of highly-selective charged particle therapy. Boron proton fusion reactions occur with highest cross section at certain proton energy level and thus can be tailored to the target volume with careful treatment planning that defines the 675 MeV proton distribution with high accuracy. Appropriate 11B compounds are required in order to achieve relevant high LET dose contribution from the boron proton-capture reaction. Previous scientific results and experiences with BNCT provide background knowledge and information regarding the optimization of boronated compound development, their characterization, measurement and imaging. However, there are substantial differences between BNCT and BPCEPT, which in turn places special unique chemical, physical and biological demands on 11B-carrier compounds for BPCEPT. In this review, we evaluate well-known and recently developed boron compounds for BPCEPT.

AB - The aim of this review was to define appropriate 11B delivery agents for boron proton-capture enhanced proton therapy (BPCEPT) taking into account the accumulated knowledge on boron compounds used for boron neutron capture therapy (BNCT). BPCEPT is a promising treatment approach which uses a high linear energy transfer (LET) dose component in conjunction with conventional proton therapy to increase the relative biological effectiveness of highly-selective charged particle therapy. Boron proton fusion reactions occur with highest cross section at certain proton energy level and thus can be tailored to the target volume with careful treatment planning that defines the 675 MeV proton distribution with high accuracy. Appropriate 11B compounds are required in order to achieve relevant high LET dose contribution from the boron proton-capture reaction. Previous scientific results and experiences with BNCT provide background knowledge and information regarding the optimization of boronated compound development, their characterization, measurement and imaging. However, there are substantial differences between BNCT and BPCEPT, which in turn places special unique chemical, physical and biological demands on 11B-carrier compounds for BPCEPT. In this review, we evaluate well-known and recently developed boron compounds for BPCEPT.

KW - BNCT

KW - Boron delivery agents

KW - Boron-neutron capture therapy

KW - Boron-proton capture enhanced proton therapy BPCEPT

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=85066423974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066423974&partnerID=8YFLogxK

U2 - 10.21873/anticanres.13343

DO - 10.21873/anticanres.13343

M3 - Review article

C2 - 31092418

AN - SCOPUS:85066423974

VL - 39

SP - 2265

EP - 2276

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5

ER -